Press Center

Practices
Industries
Jurisdictions
17 September 2025

Lidings is pleased to invite you and your colleagues to a seminar on launching new drugs in the Russian market.

Regulatory incentives and objective economic realities are driving pharmaceutical companies to seek opportunities for launching new drugs. Such projects are now being conceived and implemented not only by innovative companies but also by players who have traditionally specialized in generics and biosimilars.

During our seminar, we will share our experience and propose effective, cost-efficient legal solutions to help businesses safely and promptly execute new launches at any stage.

Overview Of Changes in Information Security and Personal Data Protection Affecting Wholesale and Retail Trade of Medicinal Products

15 July 2025

Overview of changes in the sphere of information security and personal data (hereinafter referred to as the “PD”) that will affect the activities of organizations involved in the wholesale and retail trade of medicinal products. We remind you that starting from September 1, 2025, consents for PD processing must be stand-alone documents, separate from website Privacy Policies

Lidings – Strategic Partner of the Conference on Legal Issues in Pharmaceutical Industry

10 April 2025

April 10th, 2025 annual conference Pharmaceuticals – 2025: Legal Issues will take place in Moscow organized by Pravo.ru. Lidings lawyers take an active part in the event’s program.

As a strategic partner of the conference, we aimed to make the program rich and actual. Together with pharmaceutical industry experts and lawyers, we will discuss how the market has changed in 2024 and what awaits us in 2025.

Pausing FCPA: is anti-corruption compliance on pause?

24 February 2025

On 10 February 2025, President Trump signed an executive order, "Pausing Foreign Corrupt Practices Act Enforcement to Further American Economic and National Security" ("EO"): Is anti-corruption compliance on pause?

The EO establishes a moratorium on new investigations and enforcement actions under the FCPA for 180 days (with the possibility of a 180-day extension) and directs the Attorney General to review current investigations and enforcement actions within the specified timeframe, along with a revision of the guidelines governing FCPA investigations.